X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (158) 158
Publication (21) 21
Newspaper Article (15) 15
Book / eBook (12) 12
Book Review (10) 10
Conference Proceeding (4) 4
Book Chapter (2) 2
Patent (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (82) 82
humans (72) 72
hematology (48) 48
female (43) 43
male (42) 42
middle aged (42) 42
oncology (36) 36
adult (31) 31
aged (30) 30
treatment outcome (24) 24
prognosis (21) 21
cancer (20) 20
young adult (20) 20
myelodysplastic syndromes (19) 19
aged, 80 and over (18) 18
animals (18) 18
analysis (17) 17
leukemia, myeloid, acute - genetics (17) 17
adolescent (16) 16
leukemia (16) 16
transplantation (16) 16
leukemia, myeloid, acute - mortality (15) 15
prospective studies (15) 15
germany (14) 14
leukemia, myeloid, acute - drug therapy (14) 14
risk factors (14) 14
acute myeloid-leukemia (13) 13
mds (13) 13
mice (13) 13
mutation (13) 13
stem cells (13) 13
cell biology (12) 12
stem-cell transplantation (12) 12
diagnosis (11) 11
hemic and lymphatic diseases (11) 11
hematopoietic stem cells (10) 10
abridged index medicus (9) 9
aml (9) 9
care and treatment (9) 9
chemotherapy (9) 9
myelodysplastic syndromes - drug therapy (9) 9
myelodysplastic syndromes - genetics (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
azacitidine (8) 8
bone-marrow (8) 8
cell line, tumor (8) 8
gene expression (8) 8
medicine & public health (8) 8
patients (8) 8
research (8) 8
survival (8) 8
survival rate (8) 8
activation (7) 7
cytogenetics (7) 7
fms-like tyrosine kinase 3 - genetics (7) 7
kaplan-meier estimate (7) 7
leukemia, myeloid, acute - diagnosis (7) 7
medicine, research & experimental (7) 7
mutations (7) 7
myelodysplastic syndrome (7) 7
risk (7) 7
scoring system (7) 7
studies (7) 7
transplantation, homologous (7) 7
acute myeloid leukemia (6) 6
biochemistry & molecular biology (6) 6
classification (6) 6
clinical trials (6) 6
disease-free survival (6) 6
follow-up studies (6) 6
hematology, oncology and palliative medicine (6) 6
hematopoietic stem cell transplantation (6) 6
hematopoietic stem cell transplantation - methods (6) 6
lenalidomide (6) 6
leukemia, myeloid, acute - therapy (6) 6
medical research (6) 6
progenitor cells (6) 6
recommendations (6) 6
stem-cells (6) 6
time factors (6) 6
adults (5) 5
article (5) 5
cells, cultured (5) 5
chromosome aberrations (5) 5
comorbidity (5) 5
decitabine (5) 5
differentiation (5) 5
drug therapy (5) 5
flow cytometry (5) 5
health aspects (5) 5
hematopoietic stem cells - drug effects (5) 5
immunotherapy (5) 5
internal tandem duplication (5) 5
karyotype (5) 5
medicine, experimental (5) 5
multiple-myeloma (5) 5
myelodysplastic syndromes - mortality (5) 5
nuclear proteins - genetics (5) 5
prognostic-significance (5) 5
quality of life (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1338 - 1347
Journal Article
Annals of Hematology, ISSN 0939-5555, 12/2016, Volume 95, Issue 12, pp. 1931 - 1942
Journal Article
Science, ISSN 0036-8075, 12/2017, Volume 358, Issue 6367, p. eaan4368
Kinase inhibitors are important cancer therapeutics. Polypharmacology is commonly observed, requiring thorough target deconvolution to understand drug... 
REFINEMENT | PROTEIN | CHEMICAL PROTEOMICS | INHIBITOR SELECTIVITY | DATA QUALITY | QUANTIFICATION | MULTIDISCIPLINARY SCIENCES | INTEGRATIVE GENOMICS VIEWER | SALT-INDUCIBLE KINASES | CANCER | COMPREHENSIVE ANALYSIS | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Lung Neoplasms - drug therapy | Lung Neoplasms - enzymology | Cytokines - metabolism | Humans | Drug Discovery - methods | Antineoplastic Agents - chemistry | Molecular Targeted Therapy | Xenograft Model Antitumor Assays | Leukemia, Myeloid, Acute - enzymology | Protein Kinase Inhibitors - chemistry | Animals | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myeloid, Acute - drug therapy | Antineoplastic Agents - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Proteomics - methods | Salts | Target recognition | Lung cancer | Selectivity | Drug development | Cancer therapies | Signal transduction | Biomolecules | Protein-tyrosine kinase | Tyrosine | Medical research | Imatinib | Decision making | Medical treatment | Mass spectroscopy | Tumor necrosis factor-α | Embryos | Bruton's tyrosine kinase | Mode of action | Side effects | Inhibitors | Interleukin 10 | Affinity | Drug discovery | Mass spectrometry | Acute myeloid leukemia | Drugs | Deregulation | Leukemia | Interleukin | Medical services | Clinical trials | Leucine | Kinases | Biological effects | Epidermal growth factor | Salt-inducible kinase | Xenografts | Cell survival | Epidermal growth factor receptors | Research & development--R&D | Therapeutic applications | Myeloid leukemia | Markers | Data processing | Lead compounds | Leucine zipper proteins | Signaling | Proteomics | Cancer | Index Medicus
Journal Article
Haematologica, ISSN 0390-6078, 07/2017, Volume 102, Issue 8, pp. 1378 - 1389
P27 Kip1 (p27) can prevent cell proliferation by inactivating cyclin-dependent kinases. This function is impaired upon phosphorylation of p27 at tyrosine... 
Index Medicus
Journal Article
EMBO Molecular Medicine, ISSN 1757-4676, 04/2015, Volume 7, Issue 4, pp. 477 - 487
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 12/2014, Volume 124, Issue 12, pp. 5263 - 5274
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2011, Volume 29, Issue 10, pp. 1364 - 1372
Journal Article
Journal of Medical Genetics, ISSN 0022-2593, 09/2017, Volume 54, Issue 9, pp. 640 - 650
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2012, Volume 30, Issue 12, pp. 1350 - 1357
Journal Article
Nature Medicine, ISSN 1078-8956, 07/2016, Volume 22, Issue 7, pp. 735 - 743
Immunomodulatory drugs (IMiDs), such as thalidomide and its derivatives lenalidomide and pomalidomide, are key treatment modalities for hematologic... 
MEDICINE, RESEARCH & EXPERIMENTAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | THALIDOMIDE | CEREBLON | MULTIPLE-MYELOMA CELLS | CANCER-THERAPY | CELL BIOLOGY | 5Q DELETION | LENALIDOMIDE | DEXAMETHASONE COMBINATION | MYELODYSPLASTIC SYNDROMES | T-CELLS | E3 UBIQUITIN LIGASE | Cell Cycle Proteins - drug effects | Oncogene Proteins - genetics | Peptide Hydrolases - genetics | Humans | Peptide Hydrolases - drug effects | Thalidomide - pharmacology | RNA, Messenger - metabolism | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Basigin - genetics | Basigin - drug effects | Cell Cycle Proteins - genetics | Immunosuppressive Agents - pharmacology | Myelodysplastic Syndromes - drug therapy | Peptide Hydrolases - metabolism | RNA, Messenger - drug effects | Myelodysplastic Syndromes - metabolism | Teratogenesis - genetics | Cell Cycle Proteins - metabolism | Oncogene Proteins - metabolism | Multiple Myeloma - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Oncogene Proteins - drug effects | Signal Transduction - drug effects | Basigin - metabolism | Myelodysplastic Syndromes - genetics | Immunologic Factors - pharmacology | Multiple Myeloma - genetics | Teratogenesis - drug effects | Cellular proteins | Immunity | Carcinogenesis | Health aspects | Patient outcomes | Risk factors | Proteins | Drug therapy | Multiple myeloma | Tumors | Index Medicus
Journal Article